Grippol® Quadrivalent - quadrivalent vaccine with protection against 4 strains of influenza virus (2A+2B)
Grippol® Quadrivalent vaccine has been available in Russia since 2018. It is a modern quadrivalent vaccine that
contains antigens from 4 strains of influenza viruses and the Polyoxidonium adjuvant. It is used to immunize adults
from 18 to 60 years old.
Grippol® Quadrivalent vaccine has passed all required clinical trials, demonstrating a high level of safety and
efficacy in accordance with the EMA CPMP and Russian Federation State Pharmacopoeia criteria for influenza
A multicentre, double-blind, randomized, parallel-group study of 612 people aged 18-60 years evaluated the safety,
reactogenicity and immunogenicity of the Russian quadrivalent influenza vaccine1
Clinical centers where research was conducted: FSBI “Smorodintsev Research Institute of Influenza ” of the
Ministry of Health of RF, FSBI Research Institute of Pediatric Infections (Children's Research and Clinical
Center for Infectious Diseases) of the Federal Medical and Biological Agency, Pavlov University of the Ministry
of Health of RF.
Vaccine under study: Grippol® Quadrivalent, with the following antigen composition: influenza type A virus
antigen (H1N1), influenza type A virus antigen (H3N2), influenza type B virus antigen (Yamagata strain),
influenza type B virus antigen (Victorian strain 5 μg each, and 500 μg each of Polyoxidonium® adjuvant.
- Group I:
Grippol® Plus Vaccine containing B Strain (Yamagata strain)
- Group II:
Grippol® Plus Vaccine containing B Strain (Victoria strain)
Immunogenicity of Grippol® Quadrivalent
Clinical trials showed that the vaccine met the immunogenicity criteria for inactivated influenza vaccines for all
four included strains: 1 month after vaccination of healthy volunteers, the seroconversion rates to strains A/H1N1,
A/H3N2 and B/Yamagata and B/Victoria were 65. 8%, 69.3%, 65.8% and 67.8%, and the titers fold increase was 4.9, 5.3,
5.4 and 4.8, respectively.